Evidence map›Paper›PMID 42337105›Full record

ArticleEye (London, England)2026

Prevalence of bacillary layer detachment (BALAD) in treatment naive neovascular age-related macular degeneration (nAMD) and response to treatment after loading phase of aflibercept 2 mg: PRECISE study report 9.

Dimitrios Kazantzis, Ayse Merve Keskin, Sridevi Thottarath, Heena Syed Kubravi, Abhishek Sheemar, Sobha Sivaprasad, PRECISE Study Group

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Eye (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dimitrios KazantzisNational Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.ORCID http://orcid.org/0000-0002-4145-8144
Ayse Merve KeskinNational Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.ORCID http://orcid.org/0009-0002-0310-4473
Sridevi ThottarathNational Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Heena Syed KubraviUniversity Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
Abhishek SheemarNational Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK.
Sobha SivaprasadNational Institute of Health Research Moorfields Biomedical Research Centre, Moorfields Eye Hospital, London, UK. sobha.sivaprasad@nhs.net.
PRECISE Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo estimate the prevalence of BALAD in Treatment Naïve nAMD patients in the PRECISE study and report the response after loading phase of 2 mg aflibercept treatment.

methodsThe PRECISE study included patients aged above 50 years with treatment naïve nAMD and a baseline visual acuity (VA) between 24 and 78 letters ETDRS. All participants received three monthly aflibercept 2 mg injections followed by 8-week post-treatment follow up. BALAD prevalence, baseline clinical characteristics and the visual and anatomical response to aflibercept loading were evaluated.

resultsAmong the 1981 eligible eyes, BALAD was observed in 69 eyes (3.6%). BALAD was found in 2.7% of eyes with type 1 MNV, 6.8% of eyes with type 2 MNV, 0.5% of eyes with retinal angiomatous proliferation (RAP) and in 1.6% of eyes with polypoidal choroidal vasculopathy (PCV) (p < 0.0001). Eyes with BALAD at baseline had significantly lower VA and higher CST compared to eyes without BALAD. BALAD resolved in 63 out of 69 eyes (91.3%). VA improved and CST reduced post-treatment. Fibrosis was observed in 28 (40.6%) and ellipsoid zone disruption in 55 (79.7%) out of 69 eyes in the final visit.

conclusionsThis study estimated that BALAD was present in 3.6% of eyes with treatment naïve nAMD and occurred more frequently in type 2 MNV. Although BALAD resolved in 91.3% of eyes and visual and anatomical recovery was achieved, eyes with BALAD showed a frequent early association with fibrosis and ellipsoid zone disruption at the post-loading phase visit.

Indexed as

Angiogenesis InhibitorsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsWet Macular DegenerationAgedAged, 80 and overFemaleFluorescein AngiographyHumansIntravitreal InjectionsMaleMiddle AgedPrevalenceTomography, Optical CoherenceVascular Endothelial Growth Factor AVisual AcuityafliberceptAngiogenesis InhibitorsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor A

Identifiers

PMID42337105
PMCPMC13538361

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.